CANCER VACCINES TODAY
Volume 7, Number 1
November 2009
Quick Links
Consortium Web Site
Contact Us
|
|
In This Issue...
ANNOUNCEMENTS
IN THE NEWS
INDUSTRY BEAD
ABOUT THE CANCER VACCINE CONSORTIUM
|
ANNOUNCEMENTS
MIATA Project Announced: Minimal Information About T cell-Based Immune Monitoring Assays
The Cancer Vaccine Consortium, in partnership with the Association for Cancer Immunotherapy (www.c-imt.org) and Stanford University, announce the launch of the MIATA Project, and invite members of the immunomonitoring community to participate in this important collaborative effort to establish minimal reporting guidelines for T cell-based immunoassays.
back to top
Cancer Vaccine Consortium's 2010 Colloquium and Annual Meeting Announced
SAVE THE DATE! We invite you to attend and participate in the 11th Scientific Colloquium and 9th Annual Meeting of the Cancer Vaccine Consortium, which will take place March 18-20, 2010, in Washington, DC. The meeting’s dual theme, Elucidating the Biology for Clinical Success of Cancer Vaccines and Future Outlook for Cancer Immunotherapy, brings together leaders from the scientific community, regulatory agencies, academic institutions and biopharmaceutical companies to facilitate practical progress in the field of cancer immunotherapy.
More details available soon.
back to top
Save the Date: 2010 CRI Symposium
The Cancer Research Institute will host the 18th annual conference in its International Cancer Immunotherapy Symposium Series, which will be held October 6-8, 2010, in New York City. Watch for further announcements in 2010.
back to top
ImmunoAssay Proficiency Panel Program Update
Results of CVC serum study for Elispot published
The Cancer Vaccine Consortium Elispot proficiency panel, begun in 2005, has previously identified after repeated panel rounds that serum choice used to supplement the assay medium is the leading cause of suboptimal assay performance. (Read the open access article here: http://www.springerlink.com/content/0528077jr2866u3t/)
Following the publication of these results, the CVC initiated a serum task force within the 2009 Elispot panel round. This task force would seek to determine whether commercially available serum-free media could be an alternative for serum-supplemented media in IFN-gamma Elispot experiments for human PBMC.
The results of this completed study have been published electronically ahead of print in Cancer Immunology Immunotherapy (Read the open access article here: http://www.springerlink.com/content/035q60771v570116/). The study demonstrated that serum-free media can perform at least as well as qualified serum-supplemented media in regard to antigen-specific spots and background reactivity. The recovery and viability of cells were comparable, even after overnight resting. Further, one medium was identified which appeared to enhance antigen-specific IFN-gamma production.
The results of this study present an important tool to further standardize and harmonize Elispot testing.
The recent Cancer Immunology, Immunotherapy paper was also featured on MDLinx.com: http://www.mdlinx.com/hemeonclinx/news-article.cfm/2944685.
The Elispot panels are conducted under the auspices of the CVC's ImmunoAssay Working Group (IAWG). The goal of the IAWG is to help facilitate and harmonize the immune monitoring approaches in the larger cancer vaccine community. The program’s objectives are: 1) to offer an external validation program, and 2) to enhance assay harmonization. Since its inception five years ago, the IAWG has successfully completed four rounds of Elispot proficiency panel testing, as well as the two rounds for multimer and ICS staining and one round of CFSE staining. It is the largest proficiency testing program worldwide to include participants from academic, biotechnological, pharmaceutical, and governmental backgrounds.
If you are interested in participating in this program, contact Sylvia Janetzky, the coordinator of the ImmunoAssay Working Group, at sylvia@zellnet.com.
back to top
Welcome New Members
The Cancer Vaccine Consortium welcomes its newest members: ERYtech Pharma, Johannes Gutenberg University Clinic, Mabtech AB, Trimed Biotech GmbH, University of Erlangen, and the University of Tuebingen.
ERYtech Pharma
ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma developing new high value medicinal products for unmet clinical needs in the fields of oncology and hematology. Its business model consists both of developing and selling new innovative medicinal products and of partnering with pharma/biotech companies. ERYtech Pharma’s patented technology and platform offer large possibilities to create new products and IP on an industrial scale. ERYtech Pharma has built in less than five years a strong pipeline with very ambitious programs. The ambition of the company is to become a world leader in the pharmaceutical industry using red blood cells.
Johannes Gutenberg University Clinic
Named after the famous fifteenth-century printer who revolutionized printing with movable types, Johannes Gutenberg University Mainz combines stimulating academic diversity with excellent research structures: About 500 professors and 2,300 members of our academic staff research and teach in our eleven departments and 150 institutes. The Johannes Gutenberg University Mainz is proud to host 12 Collaborative Research Centers, 9 Research Units, and 7 Research Training Groups, all funded by the German Research Foundation (DFG), as well as numerous research initiatives funded by other sources, both public and private. In addition, our campus is home to the Max Planck Institutes for Polymer Research and Chemistry. The partners of the CVC are located within the University Medical Center of the Johannes Gutenberg University. The University Medical Center has a strong focus on Immunology and Immunotherapy.
Founded in 1477, Mainz University is one of the oldest German universities. In its diversity of students, its global outlook, as well as its outstanding research it is also a university of compelling change.
Mabtech AB
Mabtech AB is a privately owned biotech company founded in 1986. Emerging from the Department of Immunology at Stockholm University, Mabtech has become a world leader in ELISpot and T-cell measurements.
Representing one of the most sensitive and easiest methods to analyze specific T-cell responses, the ELISpot is ideal whenever studying the role of T cells in e.g. infections, cancer, allergy, and autoimmune disease. With its straightforward performance and the possibility to screen large number of samples, the ELISpot has become a standard method in the research and clinical evaluations of new vaccines.
To supplement the ELISpot products, we have recently launched a series of complete, ready-to-use ELISA kits that allow easy measurements of cytokine levels in various samples including serum and plasma.
By combining innovative development and high quality, our aim is to continue providing products that meet the needs of the frontline researcher as well as those involved in clinical research with high demands for large scale screening under standardized conditions.
With a highly competent and dedicated staff, we strive to always offer the best quality products and the best possible technical support. The head office and research laboratory are located in Stockholm but in order to work closely with the research community and to be able to offer fast deliveries world-wide we also have local offices in Australia, France, Germany, and the USA. In several other countries we work via selected distributors.
Trimed Biotech GmbH
Trimed develops techniques for an immunologic treatment of cancer (cancer vaccines) based on the use of antigen-presenting IL-12 secreting dendritic cells. In cancer therapy there is a clear trend towards individualized cancer medicines based on biotechnological concepts. Trimed’s patient specific and well-tolerated cancer vaccine enables the immune system to directly recognize and destroy tumor cells.
Trimed was founded in 2003 as a subsidiary of the Children’s Cancer Research Institute (CCRI) at the St. Anna Children’s Hospital. In 2006, AOP Orphan Pharmaceuticals AG, an Austrian pharmaceutical company specializing in orphan drugs, took over majority owner ship of Trimed.
The Trimed technology was developed at the CCRI’s Laboratory of Tumour Immunology by Thomas Felzmann and his team. The whole research team has joined Trimed to continue its clinical R&D efforts in phase II and III trials. The ultimate goal of Trimed is to obtain marketing authorization and eventually commercialize Trivax.
University of Erlangen
Erlangen has a worldwide reputation as a center of medical excellence. Research, treatment and medical innovation form a nucleus of high efficiency. The Medical Valley association in the European Metropolitan Area of Nuremberg (EMN) has assumed the administration and coordination of all these activities in order to further pool and expand this concentration of expertise. Boasting a total of 68 professorships in its medical, technical and scientific faculties, the Friedrich-Alexander-University of Erlangen-Nuremberg (FAU) is one of the most important partners in these efforts. A large number of research institutes, application centers and similar organizations are already exceedingly well networked. And scientists from Erlangen and Nuremberg are now working closely with top universities from all around the world on more than 130 research collaborations.
The global market leader in medical technology, the Siemens Healthcare division, is based in Erlangen. A number of other leading international companies in the medical technology sector have now also set up in the city.
More than 60,000 patients are admitted to the University Hospital Erlangen every year. Around three times this number receive out-patient treatment at its 25 individual clinics. The oncology clinics, institutes and departments of the Erlangen University Hospital and the Medical Faculty of the Friedrich-Alexander-University have combined their resources in the University Cancer Center (UCC) Erlangen. Their joint aim is to make it possible to provide even better and more personalized treatment for cancer sufferers using the results of the latest, cutting-edge research. The UCC Erlangen is one of eleven oncology centers of excellence in Germany—and the first in Bavaria—that are supported by the organization Deutsche Krebshilfe (German Cancer Aid). In addition to the help received from the Krebshilfe, a number of European programs are also sponsoring tumor therapy (in particular melanoma treatment) using individualized vaccines based on the patient’s own dendritic cells that are produced in the Dermatology Department’s clean room laboratories and then used in studies. For 2010, the world’s first randomized preventive phase III study has been planned for patients with uveal melanomas and a particularly high risk of metastasis.
University of Tuebingen
The T-cell immunomonitoring working group, led by Dr. Cecile Gouttefangeas, is part of the Institute for Cell Biology, in the Department of Immunology at Tübingen University, Germany. The Department of Immunology is headed by Professor H-G Rammensee and its main expertise can be found in the molecular analysis of MHC-ligand interaction and T-cell function, with special interest in the immunity against cancer and immunotherapy. T-cell immunomonitoring focuses on the function of CD4 and CD8 T-cell subsets in relation to cancer. One way they are studying these cells is in patients receiving anti-cancer therapies, including immunotherapies.
The group is also interested in establishing guidelines to harmonize the assays used for T-cell immune monitoring, especially for evaluating T-cell based immunotherapies. The group is co-organizing and participating in the Cancer Immunotherapy Immunoguiding Program, an international working group of laboratories related to the Association for Immunotherapy of Cancer. The aims of which are to evaluate, compare, and improve the sensitivity and reproducibility of the techniques and protocols applied for the enumeration of antigen-specific T cell responses.
back to top
IN THE NEWS
Advaxis, Inc.
23% of Cervix Cancer Patients Treated with ADXS11-001 Remain Alive 36 Months After Initial Dosing
(Oct. 1, 2008) The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., has shown thirty-six month survival in three of the thirteen evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection. The patients had participated in the first human trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in women who have failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at three month intervals. These mortality figures substantially exceed the median survival rate established by the National Cancer Institute's Gynecologic Oncology Group, which varies between 3.8 and 6.2 months in studies of patients who have failed prior cytotoxic treatment including chemotherapy with various agents.
Read more
AlphaVax
AlphaVax Progresses a Prophylactic HSV Vaccine
(Nov. 4 2009) Recently, studies linking genital herpes simplex virus (HSV) infections to increased transmission of HIV identify another important reason to develop a vaccine against HSV. The development of an effective prophylactic vaccine against HSV is a key product opportunity for which the AlphaVax vector platform is ideally suited. Their current preclinical studies are focused on assessing the potential of their first vaccine candidate to provide broad, cross-protective responses to both HSV-1 and HSV-2 in a mouse challenge model. Preliminary results show that the first candidate is immunogenic, inducing robust humoral and cell-mediated responses, as well as efficacious, inducing complete protection against challenge with both HSV strains. Additional preclinical studies are ongoing. In parallel, AlphaVax has produced a lot of GMP-compliant clinical trial material of this vaccine and anticipates initiating a trial in early 2010.
Read more (PDF)
Antigenics
Data From Ongoing Phase 2 Trial Consistent with Survival Outcome Reported in Earlier Phase I Trial
(Oct. 26, 2009) — Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco, has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA. Data reported in the first 20 patients treated with Oncophage show a median survival of 10.1 months. While survival data continues to accrue on all patients in the study, to date six patients (30 percent) have survived at or beyond 12 months. These early data show an improvement in overall survival over the previous long standing historical median survival of 6.5 months. “These are encouraging results that suggest activity with Oncophage in this challenging patient population,” said Andrew T. Parsa, MD, PhD, associate professor in the department of neurological surgery at UCSF, and principal investigator of the trial, who presented the update.
Read more.
Argos Therapeutics
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis™ HIV Program at the AIDS Vaccine 2009 Conference
(Oct. 21, 2009) Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response, and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The presentations contained important results, including a favorable safety profile for AGS-004, the ability to induce partial to complete viral load control in the absence of antiretroviral therapy during a 12-week structured treatment interruption, and a potent and diverse immune response to AGS-004 treatment. These AGS-004 results are unprecedented for an immunotherapeutic candidate in HIV and, if confirmed in an upcoming randomized study, could lead to a new treatment paradigm for HIV.
Read more.
Bristol-Myers Squibb
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
(Oct. 23, 2009) Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data from study XL184-201 were presented during a poster session at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.The study evaluates the safety, tolerability, and clinical activity of XL184 at continuous daily doses in patients with previously treated GBM, including some patients who had received prior antiangiogenic therapy. A total of 46 patients in first or second relapse were enrolled and received daily doses of XL184.
Read more.
Celldex Therapeutics
Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
(Oct. 29, 2009) Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder, and pancreatic cancer. CDX-1307, the first candidate from the Company’s Precision Targeted Immunotherapy Platform, utilizes monoclonal antibodies to deliver vaccine directly to the patient’s immune system and focuses the immune system against hCG beta (hCG-β), a cancer-associated target believed to play a role in more aggressive forms of the disease. The data, presented at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc) in Washington, D.C., demonstrated enhanced immunological and biological responses and support the planned initiation of Phase 2 clinical trials in hCG-β expressing cancers.
Read more.
CureVac
CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer
(Nov. 2, 2009) CureVac GmbH, the mRNA vaccine company, today announced that the German authorities approved the start of the Phase IIa trial in Prostate Cancer after assessment of the first safety data of lead candidate CV9103, a RNActive®-derived mRNA vaccine. Results so far from the Phase I show CV9103 to be safe and well tolerated. The drug candidate CV9103 will be further developed for the treatment of patients with hormone-refractory metastatic prostate cancer. The Paul-Ehrlich Institut has approved the start of the Phase IIa with CV9103 to further evaluate the safety, tolerability and biological activity of the vaccine. CureVac has now launched the Phase IIa in 21 patients with CV9103 via intradermal injection (multiple-dose). First results from this trial are expected by H2 2010. "This is the first evaluation of CureVac's RNActive® platform in humans," said Ingmar Hoerr, Managing Director of CureVac. "We are confident that mRNA vaccines have the potential to become a novel class of broadly applicable therapeutic agents addressing large areas of immunotherapy. In combination with the attractive preclinical profile the results we have seen in the Phase I study strongly support our plans to develop CV9103 as a safe and efficacious treatment of prostate cancer."
Read more.
ERYtech Pharma
ERYtech Pharma starts its pivotal clinical trial for GRASPA® in Acute Lymphoblastic Leukaemia.
(Nov. 5, 2009) ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy with regard to the asparagine depletion level. GRASPA® is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical uses, compared to existing forms, due to the entrapment and protection of the enzyme inside the homologous red blood cell. GRASPA®’s interest lies in overcoming all existing limitations associated with conventional L-asparaginase through longer efficacy, better compliance, reduced dosage and an increased safety profile; making it satisfactory for every ALL patients, even high risk ones (hypersensitive, elderly patients), or patients with neutralising antibodies.
Read more.
Inovio Biomedical
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
(Oct. 5, 2009) Inovio Biomedical Corporation announced interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. GX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. This phase I clinical trial was designed to test the safety and immunogenicity of VGX-3100 in women with a previous history of cervical intraepithelial neoplasia (CIN) 2/3, a precursor lesion prior to the development of cancer. This dose escalation study is enrolling patients in three cohorts of six subjects each with DNA vaccine doses at 0.6 mg (0.3 mg each of two DNA plasmids), 2.0 mg, and 6.0 mg. The immunization regimen consists of each subject receiving three immunizations at the indicated dose. The vaccine is delivered using Inovio’s proprietary CELLECTRA® intramuscular electroporation delivery device.
Read more.
MannKind
Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies
(Oct. 29, 2009) Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting. “MKC1106-MT and MKC1106-PP met the primary end-points of both trials and, in addition, showed early evidence of clinical benefit, which marks an important step forward for MannKind’s oncology portfolio,” said Peter Richardson, MRCP, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. “These encouraging results set the stage to move into phase 2 trials with these innovative, targeted therapies, which represent the cornerstone of our cancer immunotherapy program.”
Read more.
Transgene
First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
(Nov. 4, 2009) Transgene today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical trials. Transgene’s Phase I trial will take place in six centers in France and should enroll 20 patients. The primary endpoints are to assess the safety and maximum tolerated dose of TG4023. “We are pleased to bring this new product to clinic and to expand our clinical portfolio with this innovative approach” said Philippe Archinard, Chief Executive Officer of Transgene. “The preclinical data for TG4023 has been very promising and there is a clear market need for an alternative treatment of hepatocellular carcinoma and liver metastasis for the thousands of patients for whom transplant is not possible.”
Read more.
+ + +
Share Your Updates
Does your company have news to share about important advancements in the development of cancer vaccines? If so, please forward news releases and announcements to consortium-news@cancerresearch.org.
back to top
INDUSTRY BEAD
Publications
"Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells" published in Cancer Immunology, Immunotherapy (5 November 2009) [OPEN ACCESS]. The serum task force results demonstrate compellingly that serum–free media perform as well as qualified medium/serum combinations, independent of the applied SOP. Recovery and viability of cells are largely unaffected by serum–free conditions even after overnight resting. Furthermore, one serum–free medium was identified that appears to enhance antigen–specific IFNgamma–secretion.
"MIATA—Minimal Information about T Cell Assays" published in Immunity [OPEN ACCESS]. Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV. Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.
Brian T. Weinert, Kausilia K. Krishnadath, Francesca Milano, Ayako W. Pedersen, Mogens H. Claesson and Mai-Britt Zocca. Cancer Immun [serial online] 2009; 9:9.
Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.
Midori Isobe, Shingo Eikawa, Akiko Uenaka, Yoichi Nakamura, Tetsuo Kanda, Shigeru Kohno, Kiyotaka Kuzushima and Eiichi Nakayama. Cancer Immun [serial online] 2009; 9:8.
Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.
Philippe Guillaume, Danijel Dojcinovic and Immanuel F. Luescher. Cancer Immun [serial online] 2009; 9:7.
Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer.
Nana E. Tchabo, Paulette Mhawech-Fauceglia, Otavia L. Caballero, Jeannine Villella, Amy F. Beck, Anthony J. Miliotto, Jianqun Liao, Christopher Andrews, Shashikant Lele, Lloyd J. Old and Kunle Odunsi. Cancer Immun [serial online] 2009; 9:6.
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Jianda Yuan, Geoffrey Y. Ku, Humilidad F. Gallardo, Francesca Orlandi, Gregor Manukian, Teresa S. Rasalan, Yinyan Xu, Hao Li, Shachi Vyas, Zhenyu Mu, Paul B. Chapman, Susan E. Krown, Katherine Panageas, Stephanie L. Terzulli, Lloyd J. Old, Alan N. Houghton and Jedd D. Wolchok. Cancer Immun [serial online] 2009; 9:5.
+ + +
For the latest industry and academic research news, including data reported at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting, see: http://www.cancerimmunity.org/links/news.htm
To highlight the peptide database of T-cell defined tumor antigens hosted by the journal, a direct link has been added to the journal's home page. See: http://www.cancerimmunity.org. The links to databases of interest to tumor immunologists, which were accessed via the "DATABASES" link, remain accessible via the "Links" index page.
+ + +
Do you have a publication to announce? Let us know by emailing consortium-news@cancerresearch.org.
back to top
ABOUT THE CANCER VACCINE CONSORTIUM
Consortium Mission and Vision
The Cancer Research Institute Cancer Vaccine Consortium seeks to improve patient care by making cancer vaccines part of the standard-of-care in oncology. Consortium members include many of the world's most innovative pharmaceutical, biotechnology, and academic institutions. Through collaboration, interaction, and community consensus building, Consortium members form a single voice to facilitate regulatory discussion to accelerate cancer vaccine and immunotherapy development.
The Consortium's membership of industrial and academic leaders across the United States and Europe complements the CRI/LICR Cancer Vaccine Collaborative's international network of academic clinical and laboratory centers. Working in parallel under the Cancer Research Institute, the two programs encompass all points along the cancer vaccine and immunotherapy development spectrum, from laboratory and clinical discovery, reagent production, and immune response monitoring, to therapeutic product development and approval.
back to top
Members
back to top
Join the Cancer Vaccine Consortium
Companies and academic institutions interested in becoming a member of the Cancer Vaccine Consortium should email consortium@cancerresearch.org for a membership application.
back to top
# # #